Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Grows By 562.1%

Plus Therapeutics, Inc. (NASDAQ:PSTV) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 929,600 shares, an increase of 562.1% from the February 28th total of 140,400 shares. Based on an average daily volume of 14,530,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 8.1% of the shares of the company are sold short.

Analysts Set New Price Targets

PSTV has been the subject of a number of recent analyst reports. HC Wainwright cut their price objective on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a research report on Friday. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price objective on shares of Plus Therapeutics in a research report on Friday. Finally, Ascendiant Capital Markets dropped their price objective on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, December 9th.

Plus Therapeutics Stock Down 22.7 %

Shares of PSTV traded down $0.35 during mid-day trading on Friday, hitting $1.18. 2,276,910 shares of the company’s stock were exchanged, compared to its average volume of 3,921,008. Plus Therapeutics has a 52 week low of $0.24 and a 52 week high of $2.67. The stock’s 50-day simple moving average is $1.11 and its 200-day simple moving average is $1.24. The firm has a market cap of $6.93 million, a price-to-earnings ratio of -0.46 and a beta of 0.73.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The business had revenue of $1.80 million during the quarter, compared to analysts’ expectations of $1.19 million. Analysts forecast that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.